omeprazole + lansoprazole + esomeprazole + ranitidine

The combination regimen of omeprazole, lansoprazole, esomeprazole, and ranitidine refers to a flexible anti-reflux medication protocol used in clinical research, specifically in a trial sponsored by Temple University (NCT02530879). This regimen is not a single fixed-dose combination product but a clinical intervention arm where physicians could prescribe one of three proton pump inhibitors (PPIs)—omeprazole, lansoprazole, or esomeprazole—potentially in conjunction with the H2 receptor antagonist ranitidine. The PPI components function by irreversibly inhibiting the gastric H+/K+-ATPase (proton pump) on the parietal cells of the stomach, thereby suppressing the final step of gastric acid secretion. Ranitidine acts as a competitive antagonist at the histamine H2 receptors on the parietal cells, reducing acid production through a distinct pathway. This multi-drug approach was investigated for the treatment of laryngopharyngeal reflux (LPR)-related hoarseness and dysphonia, comparing its efficacy against voice therapy.

Other names

anti-reflux therapy